Tirzepatide

Overview

Tirzepatide is a dual GLP-1/GIP receptor agonist that provides enhanced metabolic effects compared to single-agonist therapies. It has shown significant results in weight management and glycemic control.

Mechanism of Action

Activates both GLP-1 and GIP receptors, providing complementary mechanisms for glucose regulation, appetite suppression, and metabolic improvement. The dual agonism may provide superior efficacy to GLP-1 agonists alone.

Research Summary

The SURMOUNT-1 trial demonstrated average weight loss of 22.5% at the highest dose over 72 weeks, surpassing semaglutide. HbA1c reductions were also superior in head-to-head trials. Cardiovascular outcome trials are ongoing.

Dosing Information

Reported Side Effects

• Nausea and vomiting
• Diarrhea
• Decreased appetite
• Injection site reactions
• Abdominal pain
• Potential pancreatitis (rare)

Labs to monitor before & during your Tirzepatide protocol

These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.

Commonly Stacked With

Research References

• Jastreboff AM, et al. New England Journal of Medicine. 2022;387(3):205-216.